# Oragenics (OGEN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/OGEN
## Company Profile
- Ticker: OGEN
- Exchange: AMEX
- Sector: Biopharma
- Location: United States
- Tags: CNS, Infectious Disease
## Stock Data
- Close: 0.4861 USD
- Market cap: 2752293.77 USD
- Last updated: 2026-10-05
## Business Overview
Oragenics is a biotechnology company focused on infectious disease and central nervous system programs. Its story has long been about using small-cap biotech tools to pursue high-unmet-need therapeutic areas.
## Why The Stock Is Moving

As of Oct 5, 2026, OGEN closed down 0.30% at $0.4861. No new same-company headline was identified in the current news window.

## Geographic Base

Oragenics is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology.

## Business Model

The company depends on early-stage scientific validation, capital discipline, and the ability to focus its pipeline. Investors watch platform shifts, early data, and financing runway.

## Landscape Position

Oragenics occupies a speculative small-cap biotech niche. The stock is driven by whether the company can sharpen its thesis enough to sustain investor confidence.

## Future Catalysts

- Oragenics is a legacy / closeout story, so the catalysts are any remaining strategic or asset-resolution update rather than a live biotech milestone. The market is focused on residual value.

## Recent News
- 2026-07-07 12:30 EST — [Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling](https://biopharmsignal.com/news/OGEN/oragenics-achieves-full-activation-of-australian-phase-iia-trial-network-all-thr-ec4ff0b0) — Source: Oragenics
- 2026-05-19 12:45 EST — [Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21](https://biopharmsignal.com/news/OGEN/oragenics-to-present-at-sidoti-s-micro-cap-virtual-investor-conference-may-20-21) — Source: Oragenics
- 2026-05-18 12:30 EST — [ORAGENICS PROVIDES INVESTOR UPDATE](https://biopharmsignal.com/news/OGEN/oragenics-provides-investor-update) — Source: Oragenics
- 2026-05-07 12:30 EST — [Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation](https://biopharmsignal.com/news/OGEN/oragenics-signs-letter-of-intent-to-license-cardiodialysistm-technology-from-sigyn-therapeutics-to-target-tbi-induced-systemic-inflammation) — Source: Oragenics
- 2026-05-05 12:30 EST — [Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.](https://biopharmsignal.com/news/OGEN/oragenics-activates-second-site-in-phase-iia-clinical-trial-of-onp-002-for-concussion-and-mild-traumatic-brain-injury) — Source: Oragenics